Nicola Weideling, a senior manager at Oxford University, was putting on a brave face. As she lay in her hospital bed, being treated for blood clots caused by the Covid vaccine developed by Oxford in ...

The vaccine has been credited with saving millions of lives - GETTY IMAGES EUROPE/MATTHEW HORWOOD The Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical ...

RIO DE JANEIRO (Reuters) - Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or ...

European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury in ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, giving the world another important tool to halt the COVID-19 pandemic.

The University of Oxford in England has paused its pediatric trial for AstraZeneca’s COVID-19 vaccine as health regulators investigate rare cases of blood clots in some recipients, The Washington Post ...

CINCINNATI (WKRC) – A preliminary study just released from AstraZeneca found the vaccine may help keep you from not just catching the coronavirus, but also giving it to someone else. This new study ...

An experimental coronavirus vaccine developed by Oxford University and drug manufacturer AstraZeneca appears to be up to 90% effective, the two partners announced Monday. The encouraging results come ...

A COVID-19 vaccine being developed by the University of Oxford in England and AstraZeneca, a Cambridge, England-based drugmaker, showed positive results in early trials, according to research ...

Oxford Vaccine Group, part of the University’s Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAdOx1 NipahB vaccine, targeting the deadly Nipah virus. The trial involves ...